Chapel Hill biotech secures OK for human tests of potential counter to fentanyl overdoses

The Food and Drug Administration has authorized Chapel Hill-based Cessation Therapeutics to begin a clinical trial on a monoclonal antibody is designed to prevent fentanyl overdoses. Here are the details.